Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
Teng Long,1,2,* Zhoutian Yang,1,2,* Huilan Zeng,1,2,* Weijie Wu,1,2 Zhiwen Hu,1,2 Zhenyun Yang,1,2 Dandan Hu,1,2 Zhongguo Zhou,1,2 Minshan Chen,1,2 Yaojun Zhang1,2 1State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Peopl...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-10-01
|
| Series: | Journal of Hepatocellular Carcinoma |
| Subjects: | |
| Online Access: | https://www.dovepress.com/comparable-clinical-outcomes-between-transarterial-chemoembolization-o-peer-reviewed-fulltext-article-JHC |
| _version_ | 1797653514438049792 |
|---|---|
| author | Long T Yang Z Zeng H Wu W Hu Z Yang Z Hu D Zhou Z Chen M Zhang Y |
| author_facet | Long T Yang Z Zeng H Wu W Hu Z Yang Z Hu D Zhou Z Chen M Zhang Y |
| author_sort | Long T |
| collection | DOAJ |
| description | Teng Long,1,2,* Zhoutian Yang,1,2,* Huilan Zeng,1,2,* Weijie Wu,1,2 Zhiwen Hu,1,2 Zhenyun Yang,1,2 Dandan Hu,1,2 Zhongguo Zhou,1,2 Minshan Chen,1,2 Yaojun Zhang1,2 1State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People’s Republic of China; 2Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People’s Republic of China*These authors contributed equally to this workCorrespondence: Minshan Chen; Yaojun Zhang, Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Dongfeng East Road 651, Guangzhou, Guangdong, 510000, People’s Republic of China, Tel +86-20-87343828, Fax +86-20-87343585, Email chenmsh@sysucc.org.cn; zhangyuj@sysucc.org.cnPurpose: To compare the treatment efficacy and safety of transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) combined with tyrosine kinase inhibitors (TKIs) and programmed cell death protein-1 (PD-1) inhibitors for patients with unresectable hepatocellular carcinoma (HCC).Patients and Methods: 81 unresectable HCC patients were retrospectively analyzed, including 30 or 51 patients treated with either TKIs and PD-1 inhibitors combined with TACE (TTP) or HAIC (HTP), respectively. Tumor response and survival outcomes were compared.Results: The median overall survival (mOS) was 21.0 months in the TTP group and 15.0 months in the HTP group (P = 0.525; HR = 1.23; 95% CI 0.66– 2.29). The median progression-free survival (mPFS) was 6.7 months in the TTP group and 9.9 months in the HTP group (P = 0.160; HR = 0.70; 95% CI 0.42– 1.16). After Propensity Score Matching (PSM), the mOS was 21.0 months in the TTP group and 18.0 months in the HTP group (P = 0.644; HR = 1.20; 95% CI 0.56– 2.58). The mPFS was 6.4 months in the TTP group and 15.0 months in the HTP group (P = 0.028; HR = 0.49; 95% CI 0.26– 0.93). The disease control rate in overall response (90.2% vs 76.7%, P = 0.116, before PSM; 91.7% vs 75.0%, P = 0.121, after PSM) and intrahepatic response (94.1% vs 80.0%, P = 0.070, before PSM; 91.7% vs 79.2%, P = 0.220, after PSM) were higher in the HTP group than in the TTP group.Conclusion: Though including more advanced tumors, the clinical outcomes of HAIC combined with TKIs and PD-1 inhibitors are comparable to TACE-based combination therapy for unresectable HCC. Nevertheless, HTP significantly improved the PFS benefits in HCC patients with with large tumor burden or vascular invasion.Keywords: transarterial chemoembolization, hepatic arterial infusion chemotherapy, tyrosine kinase inhibitors, programmed cell death protein − 1, hepatocellular carcinoma |
| first_indexed | 2024-03-11T16:45:40Z |
| format | Article |
| id | doaj.art-c641ce16bd624a7d8f5a8fc0cf276afc |
| institution | Directory Open Access Journal |
| issn | 2253-5969 |
| language | English |
| last_indexed | 2024-03-11T16:45:40Z |
| publishDate | 2023-10-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Hepatocellular Carcinoma |
| spelling | doaj.art-c641ce16bd624a7d8f5a8fc0cf276afc2023-10-22T19:32:43ZengDove Medical PressJournal of Hepatocellular Carcinoma2253-59692023-10-01Volume 101849185987510Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular CarcinomaLong TYang ZZeng HWu WHu ZYang ZHu DZhou ZChen MZhang YTeng Long,1,2,* Zhoutian Yang,1,2,* Huilan Zeng,1,2,* Weijie Wu,1,2 Zhiwen Hu,1,2 Zhenyun Yang,1,2 Dandan Hu,1,2 Zhongguo Zhou,1,2 Minshan Chen,1,2 Yaojun Zhang1,2 1State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People’s Republic of China; 2Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People’s Republic of China*These authors contributed equally to this workCorrespondence: Minshan Chen; Yaojun Zhang, Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Dongfeng East Road 651, Guangzhou, Guangdong, 510000, People’s Republic of China, Tel +86-20-87343828, Fax +86-20-87343585, Email chenmsh@sysucc.org.cn; zhangyuj@sysucc.org.cnPurpose: To compare the treatment efficacy and safety of transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) combined with tyrosine kinase inhibitors (TKIs) and programmed cell death protein-1 (PD-1) inhibitors for patients with unresectable hepatocellular carcinoma (HCC).Patients and Methods: 81 unresectable HCC patients were retrospectively analyzed, including 30 or 51 patients treated with either TKIs and PD-1 inhibitors combined with TACE (TTP) or HAIC (HTP), respectively. Tumor response and survival outcomes were compared.Results: The median overall survival (mOS) was 21.0 months in the TTP group and 15.0 months in the HTP group (P = 0.525; HR = 1.23; 95% CI 0.66– 2.29). The median progression-free survival (mPFS) was 6.7 months in the TTP group and 9.9 months in the HTP group (P = 0.160; HR = 0.70; 95% CI 0.42– 1.16). After Propensity Score Matching (PSM), the mOS was 21.0 months in the TTP group and 18.0 months in the HTP group (P = 0.644; HR = 1.20; 95% CI 0.56– 2.58). The mPFS was 6.4 months in the TTP group and 15.0 months in the HTP group (P = 0.028; HR = 0.49; 95% CI 0.26– 0.93). The disease control rate in overall response (90.2% vs 76.7%, P = 0.116, before PSM; 91.7% vs 75.0%, P = 0.121, after PSM) and intrahepatic response (94.1% vs 80.0%, P = 0.070, before PSM; 91.7% vs 79.2%, P = 0.220, after PSM) were higher in the HTP group than in the TTP group.Conclusion: Though including more advanced tumors, the clinical outcomes of HAIC combined with TKIs and PD-1 inhibitors are comparable to TACE-based combination therapy for unresectable HCC. Nevertheless, HTP significantly improved the PFS benefits in HCC patients with with large tumor burden or vascular invasion.Keywords: transarterial chemoembolization, hepatic arterial infusion chemotherapy, tyrosine kinase inhibitors, programmed cell death protein − 1, hepatocellular carcinomahttps://www.dovepress.com/comparable-clinical-outcomes-between-transarterial-chemoembolization-o-peer-reviewed-fulltext-article-JHCtransarterial chemoembolizationhepatic arterial infusion chemotherapytyrosine kinase inhibitorsprogrammed cell death protein -1combination therapyhepatocellular carcinoma |
| spellingShingle | Long T Yang Z Zeng H Wu W Hu Z Yang Z Hu D Zhou Z Chen M Zhang Y Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma Journal of Hepatocellular Carcinoma transarterial chemoembolization hepatic arterial infusion chemotherapy tyrosine kinase inhibitors programmed cell death protein -1 combination therapy hepatocellular carcinoma |
| title | Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma |
| title_full | Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma |
| title_fullStr | Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma |
| title_full_unstemmed | Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma |
| title_short | Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma |
| title_sort | comparable clinical outcomes between transarterial chemoembolization or hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and pd 1 inhibitors in unresectable hepatocellular carcinoma |
| topic | transarterial chemoembolization hepatic arterial infusion chemotherapy tyrosine kinase inhibitors programmed cell death protein -1 combination therapy hepatocellular carcinoma |
| url | https://www.dovepress.com/comparable-clinical-outcomes-between-transarterial-chemoembolization-o-peer-reviewed-fulltext-article-JHC |
| work_keys_str_mv | AT longt comparableclinicaloutcomesbetweentransarterialchemoembolizationorhepaticarterialinfusionchemotherapycombinedwithtyrosinekinaseinhibitorsandpd1inhibitorsinunresectablehepatocellularcarcinoma AT yangz comparableclinicaloutcomesbetweentransarterialchemoembolizationorhepaticarterialinfusionchemotherapycombinedwithtyrosinekinaseinhibitorsandpd1inhibitorsinunresectablehepatocellularcarcinoma AT zengh comparableclinicaloutcomesbetweentransarterialchemoembolizationorhepaticarterialinfusionchemotherapycombinedwithtyrosinekinaseinhibitorsandpd1inhibitorsinunresectablehepatocellularcarcinoma AT wuw comparableclinicaloutcomesbetweentransarterialchemoembolizationorhepaticarterialinfusionchemotherapycombinedwithtyrosinekinaseinhibitorsandpd1inhibitorsinunresectablehepatocellularcarcinoma AT huz comparableclinicaloutcomesbetweentransarterialchemoembolizationorhepaticarterialinfusionchemotherapycombinedwithtyrosinekinaseinhibitorsandpd1inhibitorsinunresectablehepatocellularcarcinoma AT yangz comparableclinicaloutcomesbetweentransarterialchemoembolizationorhepaticarterialinfusionchemotherapycombinedwithtyrosinekinaseinhibitorsandpd1inhibitorsinunresectablehepatocellularcarcinoma AT hud comparableclinicaloutcomesbetweentransarterialchemoembolizationorhepaticarterialinfusionchemotherapycombinedwithtyrosinekinaseinhibitorsandpd1inhibitorsinunresectablehepatocellularcarcinoma AT zhouz comparableclinicaloutcomesbetweentransarterialchemoembolizationorhepaticarterialinfusionchemotherapycombinedwithtyrosinekinaseinhibitorsandpd1inhibitorsinunresectablehepatocellularcarcinoma AT chenm comparableclinicaloutcomesbetweentransarterialchemoembolizationorhepaticarterialinfusionchemotherapycombinedwithtyrosinekinaseinhibitorsandpd1inhibitorsinunresectablehepatocellularcarcinoma AT zhangy comparableclinicaloutcomesbetweentransarterialchemoembolizationorhepaticarterialinfusionchemotherapycombinedwithtyrosinekinaseinhibitorsandpd1inhibitorsinunresectablehepatocellularcarcinoma |